Efficacy Of Remibrutinib Versus Dupilumab In Chronic Spontaneous Urticaria: US Phase 3b Study Design (RECLAIM)

G. Yosipovitch, G. Mosnaim, C-E. Ortmann, N. Griswold, J. Mast, El-D. Martzloff, J. Rodrigues, J. Hawkes

Please click HERE to subscribe to news alerts of the Novartis Urticaria Knowledge Center and to receive an email notification once the publication is available

Or use this LINK to access the publication once it has been presented at the congress

ACAAI 2025, American College of Allergy, Asthma & Immunology. (ACAAI), November 6—10, 2025